Effects of antipsychotic medication on psychiatric service utilization and cost

Journal of Mental Health Policy and Economics

Volumn 8, Issue 2, 2005, Pages 83-93

  Rothbard, Aileen ^a   Murrin, Mary Rose ^b   Jordan, Neil ^c   Kuno, Eri ^a   McFarland, Bentson H ^d   Stroup, T Scott ^e   Morrissey, Joseph P ^e   Stiles, Paul G ^b   Boothroyd, Roger A ^b   Merwin, Elizabeth ^f   Shern, David L ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF NORTH CAROLINA   (United States)

^f UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG CLASSIFICATION; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL HEALTH CARE; MENTAL HEALTH SERVICE; POPULATION RESEARCH; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE;

ADULT; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; COST CONTROL; FEMALE; HEALTH EXPENDITURES; HUMANS; MALE; MEDICAID; MENTAL DISORDERS; MENTAL HEALTH SERVICES; MIDDLE AGED; UNITED STATES;

EID: 21244454774     PISSN: 10914358     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Hayhurst KP, Brown P, Lewis SW. Postcode prescribing for schizophrenia. Br J Psychiatry 2003; 182: 281-283.
2. Lieberman JA. Atypical antipsychotic drugs as a first-line treatment of schizophrenia: A rationale and hypothesis. J Clin Psychiatry 1996; 57 (suppl 11): 68-71.
3. National Institute for Clinical Excellence. Guidance on the Use of Newer (Atypical) Antipsychotic Drugs for the Treatment of Schizophrenia. Technology Appraisal Guidance 43, London: NICE; 2002.
4. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60: 553-564.
5. Kasper S, Jones M, Duchesne I, RODOS Investigator Group. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): Health economic results of an international naturalistic study. Intern Clin Psychopharmacol 2001; 16: 189-196.
6. Foster RH, Goa KL. Risperidone. A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 1998; 14: 97-133.
7. Revicki DA. The new atypical antipsychotics: A review of pharmacoeconomic studies. Expert Opin Pharmacother 2000; 1: 249-260.
8. Revicki DA. Cost-effectiveness of the newer atypical antipsychotics: A review of the pharmacoeconomic research evidence. Current Opinion in Investigational Drugs 2001; 2: 110-117.
9. Procyshyn RM, Thompson D, Tse G. Pharmacoeconomics of clozapine, risperidone and olanzapine: A review of the literature. CNS Drugs 2000; 13: 47-76.
10. Conley RR, Love RC, Kelly DL, Bartko JJ. Rehospitalization rates of patients recently discharged on a regimen of risperidone or clozapine. Am J Psychiatry 1999; 156: 863-868.
11. Drew LRH, Hodgson DM, Griffiths KM. Clozapine in community practice: A 3-year follow-up study in the Australian Capital Territory. Aust NZ J Psychiatry 1999; 33: 667-675.
12. Olfson M, Mechanic D, Boyer CA, Hansell S, Walkup J, Weiden PJ. Assessing clinical predictions of early rehospitalization in schizophrenia. J Nerv Ment Dis 1999; 187: 721-729.
13. Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics. Am J Psychiatry 2001; 158: 266-269.
14. Mojtabai R, Lavelle J, Gibson PJ, Bomet EJ. Atypical antipsychotics in first admission schizophrenia: Medication continuation and outcomes. Schizophr Bull 2003; 29: 519-530.
15. Sajatovic M, Ramirez LF, Belton J, McCormick R. Health resource utilization and clinical outcomes with risperidone therapy in patients with serious mental illness. Compre Psychiatry 1999; 40: 198-202.
16. Finley PR, Sommer BR, Corbitt JL, Brunson GH, Lum BL. Risperidone: Clinical outcome predictors and cost-effectiveness in a naturalistic setting. Psychopharmacol Bull 1998; 34: 75-81.
17. Dickson RA, Dalby JT, Williams R, Warden SJ. Hospital days in clozapine-treated patients. Canadian J Psychiatry - Revue Canadienne de Psychiatrie 1998; 43: 945-948..
18. Percudani M, Barbui C. Cost and outcome implications of using typical and atypical antipsychotics in ordinary practice in Italy. J Clin Psychiatry 2003; 64: 1293-1299.
19. Sernyak MJ, Rosenheck R, Desai R, Stolar M, Ripper G. Impact of clozapine prescription on inpatient resource utilization. J Nerv Ment Dis 2001; 189: 766-773
20. Duggan, MG. Does Medicaid pay too much for prescription drugs? A case study of atypical antipsychotics. National Bureau of Economic Research, Working Paper 9626, 2003. http:/www.nber.org/papers/w9626.
21. Tuunainen A, Wahlbeck K, Gilbody SM. Newer atypical antipsychotic medication in comparison to clozapine: A systematic review of randomized trials. Schizophr Res 2002; 56: 1-10.
22. Jerrell J. Cost-effectiveness of risperidone, olanzapine, and conventional antipsychotic medications. Schizophr Bull 2002; 28: 589-605.
23. Rosenheck R, Cramer J, Allan E, Erdos J, Frisman LK, Xu W, Thomas J, Henderson W, Charney D. Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Arch Gen Psychiatry 1999; 56: 565-572.
24. Stroup ST, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, McGee MF, Simpson GM, Stevens MC, Lieberman JA. The National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Project: Schizophrenia Trial Design and Protocol Development. Schizophr Bull 2003; 29: 15-31.
25. Human Services Research Institute. Managed Care and Vulnerable Populations Study: Adults with Serious Mental Illness. Core Paper 1: Sample Survey Component. Cambridge, MA: HSRI; 2002a.
26. Human Services Research Institute. Managed Care and Vulnerable Populations Study: Adults with Serious Mental Illness. Core Paper 2: Claims and Encounter Component. Cambridge, MA: HSRI; 2002b.
27. Murrin MR, Stiles PG, Shern DL, Boothroyd RA, Merwin E, Jordan N, Morrissey JP, McFarland BH, Stroup TS, Rothbard AB. The Use of Differing Antipsychotic Medications: Effects on Outcomes for Persons with Severe Mental Illness. Report to Eli Lilly; 2003.
28. Sernyak, MJ, Leslie, D, Rosenheck,R. Predictors of Antipsychotic Medication Change. J Behav Health Serv & Res 2005; 32 (1) 85-94.
29. Essock SM, Frisman LK, Covell NH, Hargreaves WA. Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. Arch Gen Psychiatry 2000; 57: 987-994.